FAS and FAS ligand (FASL) are the principal genes of the apoptosis pathway, which play a vital role in the etiology of various gynecological cancers. Studies have revealed that polymorphism of FASL promoter -844C>T (rs763110) influences FASL transcription process, which involving in cancer risk. Moreover, estrogen has been proved to trigger T-cell apoptosis by up-regulating FAS/FASL system in cancer cells. However, results from the published studies on the association between FASL -844C>T polymorphism and risk of gynecological cancer are conflicting. We performed a meta-analysis based on 13 case-control studies, including a total of 6256 cancer cases and 5573 controls. We used odd ratios (ORs) with 95% confidence intervals (CIs) to assess the association strength. Overall, the FASL -844CT and TT genotypes were associated with a significantly reduced risk of gynecological cancer types in homozygote comparison (OR=0.80, 95% CI=0.64–0.99), heterozygote comparison (OR=0.81, 95% CI=0.67–0.98), and dominant model (OR=0.81, 95% CI=0.67–0.98). In the stratified analyses, we observed a similar association among Asian population (heterozygote comparison: OR=0.73, 95% CI=0.56–0.95; dominant model: OR=0.75, 95% CI=0.57–0.98) and hospital-based studies (homozygote comparison: OR=0.61, 95% CI=0.43–0.86). When stratified by cancer type, there was also a significantly lower risk of the ovarian cancer in different genetic models except the recessive one. The results suggested that the FASL -844C>T polymorphism may reduce the risk of gynecological cancer.